References

DEPRESSION

1. WHO (2021), Depression factsheet: https://www.who.int/news-room/fact-sheets/detail/depression
2. WHO (2021), Depression factsheet: https://www.who.int/news-room/fact-sheets/detail/depression
3. WHO (2022), Mental health at work, The Lancet Global Health: https://www.who.int/news-room/fact-sheets/detail/mental-health-at-work
4. Antidepressant Use Among Adults: United States, 2015-2018 (2020): https://www.cdc.gov/nchs/products/databriefs/db377.htm
5. STAR*DTrial: https://www.nimh.nih.gov/funding/clinical research/practical/stard/allmedicationlevels.shtml
6. Trivedi MH., Rush AJ., Wisniewski SR., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D:  implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
7. Sim K, Lau WK, Sim J, Sum MY, Baldessarini RJ. Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials. Int J Neuropsychopharmacol. 2015 Jul 7;19(2):pyv076. doi: 10.1093/ijnp/pyv076. Erratum in: Int J Neuropsychopharmacol. 2016 Apr 27;: PMID: 26152228; PMCID: PMC4772815.
8. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002 Apr;36(4):578-84. doi:10.1345/aph.1A254. PMID: 11918502.
9. Carbonaro, T. M., & Gatch, M. B. (2016). Neuropharmacology of N,N-dimethyltryptamine. Brain Research Bulletin, 126, 74–88. https://doi.org/10.1016/j.brainresbull.2016.04.01
10.  Based on comparison to current antidepressant therapies available
11. Based on current data on efficacy of psilocybin to treat TRD (see Carhart-Harris, R.L., Roseman, L., Bolstridge, M. et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep 7, 13187 (2017). https://doi.org/10.1038/s41598-017-13282-7) and mechanistic data to suggest similar mechanism of action of DMT to psilocybin